Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-M14D1 |
| Synonyms | |
| Therapy Description |
BL-M14D1 is an antibody-drug conjugate (ADC) targeting DLL3, which potentially induces antitumor activity (J Clin Oncol 2026 44:16_Suppl, 3001). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-M14D1 | BL M14D1|BLM14D1 | DLL3 Antibody 11 | BL-M14D1 is an antibody-drug conjugate (ADC) targeting DLL3, which potentially induces antitumor activity (J Clin Oncol 2026 44:16_Suppl, 3001). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07080242 | Phase I | BL-M14D1 | Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Recruiting | USA | 2 |